/
CERT
$6.36+$0.52 (+8.90%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$908.5M
156M shares
52-week range
$4.45 – $13.88
20% from low
Sector
SERVICES-PREPACKAGED SOFTWARE
Exchange
NASDAQ
CS
Borrow rate
0.38%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-21.53
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $163.7M | $208.5M | $243.5M | $286.1M | $335.6M | $354.3M | $385.1M | $418.8M |
| Cost of revenue | $71.0M | $79.8M | $100.8M | $111.6M | $132.6M | $141.0M | $154.5M | $161.1M |
| Gross profit | $92.7M | $128.7M | $142.8M | $174.5M | $203.1M | $213.3M | $230.6M | $257.7M |
| Gross margin | 56.6% | 61.7% | 58.6% | 61.0% | 60.5% | 60.2% | 59.9% | 61.5% |
| R&D | $10.5M | $11.6M | $19.6M | $20.4M | $28.2M | $34.2M | $37.1M | $41.0M |
| Operating income | −$4.7M | $19.6M | −$24.4M | $13.6M | $32.5M | −$40.8M | −$1.7M | $21.0M |
| EBITDA | $32.3M | $60.4M | $17.9M | $58.6M | $89.0M | $23.8M | $72.4M | $83.9M |
| Net income | −$33.3M | −$8.9M | −$49.4M | −$13.3M | $14.7M | −$55.4M | −$12.1M | −$1.6M |
| Net margin | -20.3% | -4.3% | -20.3% | -4.6% | 4.4% | -15.6% | -3.1% | -0.4% |
| EPS (diluted) | -0.25 | -0.06 | -0.32 | -0.09 | 0.09 | -0.35 | -0.08 | -0.01 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $399M | $0.38 | $0.37–$0.40 | 6 |
| 2027 | $406M | $0.41 | $0.37–$0.43 | 6 |
| 2028 | $434M | $0.51 | $-1.21–$2.23 | 2 |
| 2029 | $457M | $0.55 | $0.54–$0.57 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$6.33
Price
$6.36
Implied downside
-0%
Peer comparison
Certara, Inc. Common Stock
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
www.certara.com- Employees
- 1,576
- IPO / List date
- Dec 11, 2020
- HQ
- RADNOR, PA
Held by traders on TradeandTell
No one on the platform currently holds CERT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 354,500 | $2.0M |
| Bridgewater Associatesas of 2025-09-30 | 19,122 | $233.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CERT yet.
